- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01610648
Improving the STOP-Bang Screening Questionnaire for Patients With Sleep Apnea
Improving the Sensitivity and Specificity of the STOP-Bang Screening Questionnaire for Patients With Obstructive Sleep Apnea
The study is being conducted to test the ability of a simple questionnaire to detect mild, moderate or severe obstructive sleep apnea. The investigators are also investigating whether adding the size of the neck and waist can add to the accuracy of the questionnaire.
The study will be conducted at the Center for Sleep Medicine at Tufts Medical Center. The investigators hope to enroll 250 patients in our study at Tufts Medical Center.
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
We will complete a 12 item questionnaire and data sheet with the study subjects based on their responses and 2 measurements specified below, right before application of a study the start of their sleep study called "Polysomnography".
If available, we will also use information from the subjects medical record, including information regarding a history of diabetes (blood sugar that is too high), high blood pressure and laboratory data such as blood sugar and blood lipids (fats in the blood). We will record this information for research purposes.
The 2 measurements performed for research purposes consist of the size of the neck and waist using a flexible tape measure. After the sleep study, we will also use results from that study in this research. We expect the subjects study participation to be completed in 30 minutes or less.
There will be no follow up. If a participant cannot complete the sleep study for any reason, the study team may decide to withdraw the subject's participation without further notice.
The study will be open for participation from June 2012 through November of 2012.
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02111
- Sleep Center, Tufts Medical Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Referral to the sleep center for a diagnostic study
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
---|
Patients presenting for a diagnostic sleep study
Patients presenting to the TMC sleep center for sleep study
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Cut-off value determination for each of three STOP-Bang versions
Tidsram: The outcome measure will be assessed after aggregate data analysis has been completed. It is expected for January 2013 (up to 2 years)
|
Determine the best cutoff value using receiver-operating characteristics curves separately for each of the 3 versions of the STOP-Bang questionnaire (original, re-weighted, Stop-Bang MEtS) for subjects with confirmed mild, moderate and severe sleep apnea according to the Apnea-Hypopnea Index AHI as defined by the society for sleep medicine.
The cut-off values will be calculated separately for each category of severity.
|
The outcome measure will be assessed after aggregate data analysis has been completed. It is expected for January 2013 (up to 2 years)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Cut-off value determination for each of three STOP-Bang versions
Tidsram: The outcome measure will be assessed after aggregate data analysis has been completed. It is expected for January 2013 (up to 2 years)
|
Determine the best cutoff value using receiver-operating characteristics curves separately for each of the 3 versions of the STOP-Bang questionnaire (original, re-weighted, Stop-Bang MEtS) for subjects with confirmed mild, moderate and severe sleep apnea according to the Oxygen Desaturation Index ODI as defined by the Society for sleep medicine.
The cut-off values will be calculated separately for each category of severity.
|
The outcome measure will be assessed after aggregate data analysis has been completed. It is expected for January 2013 (up to 2 years)
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Roman Schumann, MD, Tufts Medical Center
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- IRB#10391
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Metaboliskt syndrom
-
Grand Valley State UniversityAnmälan via inbjudanMetabolic Associated-dysfunction Steatotic Lever Disease (MASLD) | Metabolic Associated-dysfunction Steatohepatit (MASH)Förenta staterna
-
Scripps Whittier Diabetes InstituteAvslutadCardio-metabolic Care-Team Intervention (CMC-TI)
-
Shanghai General Hospital, Shanghai Jiao Tong University...Har inte rekryterat ännuPrediabetes | Kontinuerlig glukosövervakning | Metabolic Management Center
-
Brian JonasNational Cancer Institute (NCI); Celgene; Pharmacyclics LLC.AvslutadTidigare behandlat myelodysplastiskt syndrom | Myelodysplastiskt syndrom | Terapierelaterat myelodysplastiskt syndrom | Sekundärt myelodysplastiskt syndrom | Refraktärt högrisk myelodysplastiskt syndromFörenta staterna
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)AvslutadTidigare behandlade myelodysplastiska syndrom | Sekundära myelodysplastiska syndrom | de Novo myelodysplastiska syndromFörenta staterna
-
National Cancer Institute (NCI)AvslutadTidigare behandlade myelodysplastiska syndrom | Sekundära myelodysplastiska syndrom | de Novo myelodysplastiska syndromFörenta staterna
-
TJ Biopharma Co., Ltd.Rekrytering
-
National Heart, Lung, and Blood Institute (NHLBI)National Cancer Institute (NCI)RekryteringMyelodysplastiska syndrom (MDS)Förenta staterna, Israel
-
AbbVieCelgene; Genentech, Inc.AvslutadMyelodysplastiska syndrom (MDS)Förenta staterna, Australien, Tyskland
-
AbbVieGenentech, Inc.Aktiv, inte rekryterandeMyelodysplastiska syndrom (MDS)Förenta staterna, Australien, Kanada, Frankrike, Tyskland, Italien, Storbritannien